Non-HDL-C and ApoB: Cargo and particle count together
Non-HDL cholesterol / apolipoprotein B (Non-HDL-C / ApoB) blood testing examines the cholesterol carried by all "delivery" particles except HDL and the key protein that labels each one. Non-HDL cholesterol (non-HDL-C) is the cholesterol contained in low-density and very-low-density lipoproteins and their relatives (LDL, VLDL, IDL, remnant particles, lipoprotein(a)). Apolipoprotein B (ApoB) is the structural backbone protein on these particles—each atherogenic particle carries one ApoB—produced mainly in the liver and intestine as lipoproteins are assembled.
These measures describe how cholesterol is packaged and trafficked in the bloodstream. Non-HDL-C shows the total cholesterol cargo available for delivery to tissues, while ApoB indicates the number of circulating atherogenic particles (particle number). ApoB-containing lipoproteins transport triglyceride and cholesterol from the liver and gut to muscle, fat, and other organs, and they bind to cellular docking sites such as the LDL receptor. Because it is the particles that can enter the artery wall, their count and cargo together summarize the blood's atherogenic load—how many cholesterol-carrying vehicles are present and how much cholesterol they carry.
Why particle count plus cargo beats LDL-C alone
Non-HDL cholesterol and apolipoprotein B quantify the atherogenic particles that carry cholesterol through your bloodstream and seed plaque in artery walls. Non-HDL sums all "bad" cholesterol cargo; ApoB counts the number of those particles themselves. Together they reflect the traffic load your heart, brain, kidneys, and limbs experience. For risk, lower is generally better; most labs define a normal range, but within reference ranges tends to sit toward the lower end.
Together they quantify the atherogenic lipoprotein burden that drives plaque formation, influencing cardiovascular and cerebrovascular risk, endothelial function, and lipid-based energy transport.
Reading non-HDL-C and ApoB from low to high
Typical values vary by life stage. Children and teens often run lower. Men average higher than premenopausal women; values in women rise after menopause. Pregnancy naturally increases both as part of fetal growth and hormone production.
When these measures are low, they signal fewer plaque-forming particles and are usually protective. Extremely low levels can point to uncommon conditions such as genetic hypobetalipoproteinemia, malabsorption, hyperthyroidism, or severe liver disease. In those rare settings, people may notice oily stools, easy bruising, or neurologic/vision problems from fat-soluble vitamin deficiency.
Low values usually reflect reduced production or increased clearance of ApoB particles. This occurs with hyperthyroidism, liver dysfunction, malnutrition, inflammatory illness, or rare genetic hypobetalipoproteinemia. Very low ApoB may impair fat-soluble vitamin transport. Children and premenopausal women tend to sit lower than men.
Being in range suggests sufficient lipoprotein transport for hormone synthesis and cell membranes without excess atherogenic drive. It points to balanced hepatic VLDL output, insulin sensitivity, and quiet vascular inflammation. For cardiovascular protection, consensus places "optimal" toward the lower end of usual laboratory intervals.
When they are high, there are too many ApoB-containing particles (LDL, VLDL, IDL, remnants, Lp(a)), which infiltrate arteries, accelerate atherosclerosis, and link tightly to heart attack, stroke, and peripheral artery disease. This often travels with insulin resistance, fatty liver, chronic kidney disease, and, in familial forms, tendon xanthomas. Symptoms are usually silent until a vascular event.
High values usually reflect an excess of ApoB particles from hepatic VLDL overproduction (insulin resistance), reduced clearance (too little thyroid hormone, kidney disease), or genetic conditions like familial hypercholesterolemia or high Lp(a). This raises endothelial retention, foam-cell formation, and plaque growth, affecting heart, brain, and limbs. Men and older adults run higher; late pregnancy physiologically raises both.
Sample conditions and the lp(a) discordance wrinkle
Non-fasting samples are fine for non-HDL-C; ApoB changes little with meals. Acute illness can transiently lower values. Hormones, retinoids, steroids, and lipid-lowering drugs shift results. Non-HDL-C includes Lp(a) cholesterol; ApoB counts Lp(a) particles but not their cholesterol. ApoB–non-HDL-C discordance can refine risk.
Non-HDL-C and ApoB as long-term risk anchors
Big picture: Non-HDL-C and ApoB sit at the crossroads of liver production, intestinal absorption, thyroid status, and metabolic health. Persistently elevated levels strongly predict cardiovascular events and out-perform LDL-C alone, making them core gauges of long-term vascular risk and whole-body lipid handling.
FAQs
Non-HDL-C / ApoB testing measures atherogenic cholesterol (non-HDL-C) and the number of atherogenic particles (ApoB) to quantify plaque-driving burden and cardiovascular risk.
Establish a baseline, retest 6–12 weeks after lifestyle or medication changes, then every 3–12 months based on stability and goals.
Diet (saturated/trans fats, refined carbohydrates), weight, physical activity, alcohol, smoking, thyroid and kidney function, pregnancy and menopause, genetics, certain medications, acute illness, and triglyceride levels.
Nonfasting testing is reliable. For consistency with prior results, an optional 9–12 hour fast and avoiding heavy alcohol or intense exercise the day before can help comparability.
Non-HDL-C is calculated as total cholesterol minus HDL-C and is robust in fasting and nonfasting states. ApoB is directly measured with standardized assays; repeating a test can confirm unexpected results.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Feingold, K. R. (2024). Introduction to lipids and lipoproteins. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305896/
- Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011). A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes, 4(3), 337-345. https://doi.org/10.1161/CIRCOUTCOMES.110.959247
- Brunner, F. J., Waldeyer, C., Ojeda, F., Salomaa, V., Kee, F., Sans, S., Thorand, B., Giampaoli, S., Brambilla, P., Tunstall-Pedoe, H., Moitry, M., Iacoviello, L., Veronesi, G., Grassi, G., Mathiesen, E. B., Söderberg, S., Linneberg, A., Brenner, H., Amouyel, P., ... Blankenberg, S. (2019). Application of non-HDL cholesterol for population-based cardiovascular risk stratification: Results from the Multinational Cardiovascular Risk Consortium. The Lancet, 394(10215), 2173-2183. https://doi.org/10.1016/S0140-6736(19)32519-X
- Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., Watts, G. F., Borén, J., Fazio, S., Horton, J. D., Masana, L., Nicholls, S. J., Nordestgaard, B. G., van de Sluis, B., Taskinen, M. R., ... Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
- Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R., ... Wiklund, O. (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias. European Heart Journal, 41(1), 111-188. https://doi.org/10.1093/eurheartj/ehz455






































.avif)

